Microbial Proteins & Enzymes - MycoVista Biotech

Design → GMP, without detours

Dual hubs: San Diego, CA (Southern California) & Montréal, Canada
Scope: Recombinant enzymes and proteins from E. coli, Bacillus, Corynebacterium, Lactococcus, and yeasts (Pichia, Saccharomyces, Kluyveromyces), plus filamentous fungi (Aspergillus) when secretion wins. Batch, fed-batch, intensified, and continuous options—bench to 50,000 L stainless for qualified programs. End-to-end: design, strain/host, upstream, downstream, analytics, formulation, stability, and fill–finish under a unified digital QMS (ALCOA+).

Microbial proteins and enzymes are the original workhorses of biopharma—and they still set the pace when speed, cost, and scale have to coexist. But “fast and cheap” means very little without manufacturability by default: oxygen transfer that still closes at 10,000–50,000 L, impurity maps that behave in real buffers (not slideware), and documentation that convinces the sternest auditor. At MycoVista, we build the whole system—host, vector, process, analytics, formulation, and evidence—so your enzyme or protein is not only expressed; it is released and repeatable.

Why teams choose MycoVista for microbial proteins & enzymes

Longer context: Choosing microbes is a strategic choice, not a consolation prize. You pick microbes when timelines are tight, gram-per-day economics matter, and you want thermotolerant, robust production that does not depend on fragile post-translational modifications. You stay with microbes when you realize the process physics, impurity control, and documentation are already aligned to large reactors and tight budgets. Our role is to keep every decision honest—from first liter to first PPQ.

Established. Technical. Audit-ready. That’s our default.

End-to-end ownership. Strain engineering → USP (batch/fed-batch/continuous) → DSP (clarification/capture/polish) → formulation → aseptic DP—harmonized across two synchronized facilities with one digital QMS (ALCOA+).
Depth where programs crack. High-cell-density E. coli, methanol-managed Pichia (or methanol-free logic), secretion in Bacillus/Corynebacterium, and filamentous fungi with gnarly rheology—plus inclusion-body/refold programs that actually close.
Analytics first. We set acceptance criteria before DoE. We trend activity, purity, topology (for pDNA adjacencies), endotoxin, and stability; then we lock design spaces only after the evidence agrees.
Operator reality. We design oxygen transfer, shear envelopes, and filter trains for the night shift, not only the demo run. If it won’t scale or pass inspection, it doesn’t ship.

Background: when microbes beat everything else

Longer context: Microbial systems win when biology doesn’t demand complex mammalian PTMs, when volumetric productivity and short cycle times matter, and when the final presentation benefits from the ruggedness of microbial proteins. Industrial enzymes, diagnostic reagents, processing aids, and a growing class of therapeutic enzymes (including pro-enzymes and enzyme domains) are all examples where microbes are first choice. Even when a mammalian biologic is the endpoint, microbial expression often underwrites the enabling enzymes and reagents that keep your CMC program moving. In other words: microbes are not a side quest—they are the backbone of many Design → GMP stories.

From QTPP to control strategy (what we write down—and run)

Longer context: Every successful modality page starts with the same spine: what the patient or product needs (QTPP), which attributes prove we hit the mark (CQAs), and which knobs we can actually turn at scale (CPPs). We do this in plain language first, and only then in protocols and batch records.

QTPP (what must be true): dose/presentation (liquid or lyo), specific activity at use strength (for enzymes), acceptable purity/aggregate profile, endotoxin and bioburden safety, residual DNA/proteins and processing aids, shelf life and shipping truth.
CQAs (what we will measure): identity (intact mass/peptide mapping), purity (CE-SDS/SEC-MALS), activity (linked to mechanism and formulation), endotoxin, host-cell proteins/DNA, residual lysis agents/conditioners, pH/osmolality, visible/subvisible particulates, and stability.
CPPs (what we can control): host/construct, feed/induction, pH/DO/temperature, antifoam and shear budgets, clarification chemistry, capture loading/residence, polishing gradients and ionic strength, UF/DF TMP/cross-flow, and formulation buffers/excipients.

Deliverable: a control strategy that ties every CQA to a method and a unit operation—codified in SOPs, protocols, and batch records.

Host & expression architecture (choose what runs, not what flatters)

Longer context: Host selection is not tribal loyalty; it is a risk ledger. We weigh secretion versus intracellular yield, PTM needs, protease backgrounds, solvent/explosion envelopes (for induction), and downstream friendliness.

E. coli — fastest path for cytosolic proteins, periplasmic expression for easier recovery and fewer endotoxin headaches, and inclusion-body routes when refold economics win. Redox-aware strains help with disulfide-rich targets; periplasmic routes reduce protease and endotoxin pain upstream of DSP.
Pichia / Saccharomyces / Kluyveromyces — secreted proteins when secretion buys you DSP simplicity; glycerol→methanol induction or methanol-free regimes when EH&S or scale conditions favor it; oxygen-safe strategies protect induction and quality.
Bacillus / Corynebacterium / Lactococcus — robust secretion platforms for enzymes; we actively manage protease backgrounds and wall traffic.
Aspergillus (filamentous fungi) — the go-to for certain secreted enzymes; we plan for viscosity, oxygen transfer, and de-plugging downstream at design time, not as a rescue later.

Decision memo: one recommended host/route, one credible back-up, and the evidence for both. We commit to a path and avoid reality rewrites mid-campaign.

Advanced strain development (expression that behaves at scale)

Longer context: The fastest way to lose months is to win a shaky demo run. We gate clones on manufacturability, not just titer.

Architecture & selection. Promoters and regulatory elements tuned to production mode; copy number sanity; selectable markers that won’t paint you into a regulatory corner.
Stability & productivity gates. Genetic stability under process-like feed/temperature/pH; qP and specific activity (for enzymes) tracked under stress; topology for pDNA adjacencies if needed.
Quality flags early. Truncation, misfolding, glycan heterogeneity (for yeast/fungi), and proteolysis flagged before we ink a DoE.
Banking & traceability. Research → master → working banks with identity, purity, viability; chain of custody sits in eBMR/eBR from day one.

Upstream process development (oxygen, carbon, and time—balanced)

Intro: Upstream is where optimism meets physics. We design for headroom, not hero days, because kLa, OUR, heat removal, and foam will not negotiate at 10,000–50,000 L.

Feeding strategies. Carbon-limited fed-batch with controlled uptake to avoid overflow metabolism; induction choices mapped to product class (protein, enzyme, pDNA). For Pichia, we run mass-balance logic for glycerol→methanol (or methanol-free) with explosion-safety envelopes that EH&S actually signs.
Temperature & pH choreography. Induction temperature shifts to protect folding while preserving productivity; pH windows that help secretion and set up resin compatibility downstream.
DO cascades & gas logic. We size air/O₂ blending, back-pressure, and antifoam strategies to the real kLa we will have at pilot and production.
Microbial continuous and intensified. Chemostat/retentostat only when validation and cleaning strategies survive audit; high-cell-density E. coli with uptake caps to prevent acetate spikes and respiratory collapse.
PAT for decisional days. Off-gas (O₂/CO₂) and soft sensors for OUR/OTR and growth; spectroscopy/capacitance where justified; we calibrate against reference analytics so the dashboard is truthful, not decorative.

Downstream designed with upstream (clarification → capture → polish)

Intro: Downstream begins when we design upstream. Filter trains, DNA management, and capture loading limits live in the first process memo—not the last.

Clarification & primary recovery. Centrifugation and depth-filtration trains with pressure–throughput curves measured at scale-down; flocculation/conditioning only if it de-risks fouling without haunting validation. Inclusion-body programs: mechanical/chemical lysis plans that don’t poison capture or balloon endotoxin.
Capture that scales.
- Proteins/enzymes: AEX/CEX/HIC/mixed-mode by pI/hydrophobicity and impurity maps; affinity only if lifecycle economics win; multi-column when it truly lowers cost of goods.
- Periplasmic harvests: osmotic-shock logic tuned for impurity release and viscosity.
- Fungal secretions: staged filters and viscosity-aware trains; we design to de-plug, not to hope.
Polishing with a map. Ion exchange for charge noise, HIC for misfolded/aggregate clean-up, mixed-mode when single mechanisms fail; membrane options when scale punishes SEC.
UF/DF & formulation set-up. MWCO by hydrodynamic radius; staged diafiltration to avoid shear or osmotic shock; excipient and salt windows that preserve activity, not just appearance.

Artifacts: mass balance, recovery, and impurity-clearance data per step—trended, not cherry-picked.

Inclusion bodies & refold (when economics point that way)

Intro: Inclusion-body routes win when expression is huge and folding can be engineered rationally. They fail when refold is treated like alchemy. We treat refold like a first-class unit operation.

Denaturation & refold screens that test pH, redox couples, chaotropes, and additives; we measure activity, not just “solubility,” as the scoreboard.
Kinetics & mixing. We design addition profiles (and impeller choices) to avoid local supersaturation or aggregation; we prove results with scale-similar hydrodynamics.
Refold-aware DSP. Capture and polish tuned to refold intermediates; we prevent re-aggregation by pH/ionic strength discipline and temperature control.

Analytics that tell the truth (orthogonal by default)

Intro: Enzymes and microbial proteins are judged by function as much as form. Our methods read both.

Identity & purity — intact mass, peptide mapping (LC-MS); CE-SDS (R/NR); SEC-MALS for monomer/aggregate distribution; for secreted yeast/fungal proteins, glycan profiling where risk warrants.
Activity & potency — mechanism-appropriate assays with clear acceptance criteria; thermal stability and pH-rate profiles linked to formulation.
Process residuals — endotoxin (front-and-center), host-cell proteins/DNA, residual lysis agents/precipitants, antibiotic carryover if used; detergent residuals if applicable.
Stability — forced degradation (heat, shear, pH, oxidation) to map failure modes, and real/accelerated storage that matches your supply chain.
In-process control — at-line titer/activity, viscosity/turbidity, and conductivity mapping so steps stay in family.

Lifecycle: development → transfer (dual hubs) → qualification/validation; OOS/OOT governance; change control with comparability plans.

Formulation & drug product (what the dose must be)

Intro: Enzymes don’t just need to be pure; they must work at dose and survive shipping. We design liquids and lyo cycles from function back to physics.

Liquid formulations — buffers, pH, salts, and stabilizers chosen to preserve activity and limit visible/subvisible particulates; surfactants only when they earn their place.
Lyophilization — cycle design from collapse/eutectic mapping; bulking/stabilizers that create elegant, reconstitutable cakes; residual-moisture targets and reconstitution time enforced.
Container/device — vial or PFS depending on route; extractables/leachables strategies scaled to risk; sterile filtration feasibility studied early (and honestly).
Hold times & shipping — validated holds and lanes that mirror reality; we print time-out-of-refrigeration rules someone on a loading dock can actually follow.

Validation & PPQ readiness (closing the loop)

Intro: PPQ should feel like execution, not a stunt. That demands design spaces that operations can hold, cleaning validation that reads cleanly, and viral/bioburden safety that is engineered—not wished.

Design space → recipes — ranges and interlocks from development show up in batch records; alarms are meaningful, not cosmetic.
Cleaning validation — worst-case soils and MACO/PDE logic; swab/rinse methods validated for recovery; lifecycle verification on a schedule.
Hold-time & microbial control — studies aligned to process and DP; bioburden, endotoxin, and environmental monitoring (EM) trends are part of the story.
Continuous options — when adopted, we validate residence-time distributions and batch definitions that calm QA and survive audit.

Facilities & scale (what you can count on)

Intro: Big promises are easy. Big reactors are not. We list the relevant bones so you can judge.

Fermentation — benchtop and pilot suites through 50,000 L stainless (qualified programs), CIP/SIP with validated sequences; O₂ enrichment and pressure-rated gas handling; explosion-safety envelopes for methanol where relevant.
Containment & safety — ATEX-aware designs for yeasts; waste-gassing & odor control for fungal runs; closed transfers for potent materials.
DSP — pilot to GMP chromatography/TFF skids; staged depth filters; viral filtration capability where program context requires; recipe-controlled diafiltration.
Cleanrooms — ISO 8/7 with unidirectional flows; BSL-2 where required; validated utilities (HPW/clean steam/compressed air) with trending.
Analytics & support — HPLC/UPLC, LC-MS access, CE-SDS, icIEF, SEC-MALS, PCR/ELISA; osmolality, DLS; stability chambers; LN₂ storage for banks.
Digital backbone — validated CDS/LIMS/ELN and eBMR/eBR with audit trails, access controls, and versioning aligned to ALCOA+.

Regulatory & QMS posture (how the file reads)

Intro: Reviewers don’t read enthusiasm; they read evidence. We write your story so it is easy to follow and hard to shake.

QbD for real — QTPP → CQAs → CPPs mapped in protocols and transcribed into batch records; DoE in reports, not in slide decks.
Digital QMS (ALCOA+) — deviation/CAPA, change control, investigations, and training mirrored across San Diego & Montréal; audit trails that explain themselves.
Regulatory authoring — CMC sections written from actual methods and data; reviewer Q&A answered with stats plans and raw tables.
Inspection readiness — validation summaries, mass-balance tables, cleaning files, EM trend reports, and stability bins available without scavenger hunts.

Program Onboarding (your first 30 days)

Intro: Speed helps only when outputs are inspection-grade. We front-load the work that prevents rework.

A phase-appropriate control strategy mapping QTPP → CQAs (activity, purity, endotoxin/bioburden, residuals, stability) → CPPs (host/construct, feed/induction, pH/DO/temperature, clarification chemistry, capture/polish limits, UF/DF recipe, formulation).
A DoE plan for feed/induction/OTR, clarification and capture screens, polishing interactions, and UF/DF with sampling plans and pass/fail criteria; plus a formulation & stability outline tied to route and presentation.
A Gantt & risk map (FMEA) with decision gates to IND/registration; for Pichia, an induction safety plan; for inclusion-body routes, a refold dossier hypothesis; for high-endotoxin risks, an endotoxin control plan end-to-end.

Start: share target, activity units, presentation (liquid/lyo), dose/route, desired scale, and stability targets. We return a design space, unit-op parameters, and a documented path to GMP.

Typical timelines (indicative, biology- and physics-gated)

Intro: We don’t promise calendars your molecule won’t keep. We put gates, pass criteria, and fast paths on paper.

Feasibility (2–6 weeks) — host/route choice, early expression, initial clarification behavior, capture shortlist, and activity assay handshake.
Development (2–4 months) — feed/induction DoE, pH/temperature tuning, clarification and capture limits, polishing interactions, UF/DF recipe, and formulation draft.
Engineering runs — scale-similar hydrodynamics, pressure-throughput curves, mass balance and trending; hold-time studies; aseptic readiness if DP in scope.
Lock — process description with CPP ranges; method files with qualification/validation plans; stability enrollment; CMC text ready.

Tech transfer & rescue (when programs arrive mid-story)

Intro: Many microbial programs show up with great expression and unreliable lots. We stabilize first, then optimize.

Document triage — methods, deviation history, stability, change controls, resin/membrane lifecycles, endotoxin incidents.
Gap map — which CQAs are unguarded, which CPPs drift, fastest safe fixes (oxygen transfer, filter trains, refold kinetics, ionic-strength traps).
Stabilize → optimize → re-lock — interim setpoints to stop failures; targeted DoE on real drivers; comparability to bridge changes; lifecycle files updated.

ESG & supply chain (reliability is a quality attribute)

Intro: Reliability is partly ethics, partly engineering. We do both.

Sane disposables — closed, single-use where they cut contamination risk and setup time; stainless where cleaning validation and cost win.
Criticals strategy — qualified alternates for feeds, antifoam, membranes, resins, filters, and plastics; stocking plans sized to campaign risk.
Utilities stewardship — oxygen and water awareness at large scale; solvent handling and emissions managed responsibly—documented where it matters.

Deliverables (what you can hold)

Intro: Deliverables are how you know the work happened—noted, reviewed, and defensible.

Control strategy (QTPP → CQAs → CPPs) and process description with design space and limits.
Banking dossier (research/MCB/WCB) with identity/purity/viability and stability enrollment.
Analytics package — methods; transfer; qualification/validation; activity panels; trending.
DSP package — clarification map, capture limits, polishing interactions, UF/DF specs, endotoxin control evidence.
Formulation & DP — liquid or lyo dossier; filtration feasibility; inspection/CCIT plan if DP in scope.
Stability protocols/data with shelf-life rationale matched to presentation.
Batch records (eBMR/eBR) and CMC text for IND/IMPD and beyond.

Frequently asked (straight answers)

Intro: We keep answers short because production will read them.

Secreted enzyme in yeast or fungi? Yes—yeast for speed/simplicity; filamentous fungi when kinetics and secretion demand. We design for viscosity and de-plugging from day one.
Inclusion bodies—worth it? When expression is high and refold is engineerable. We treat refold like a unit operation with kinetics, mixing, and activity as the scoreboard.
Endotoxin—how early? Day one. It’s a process attribute, not a release surprise. We engineer clearance in USP and DSP.
Continuous fermentation? Only when validation and operations win. Otherwise, robust fed-batch beats romance every time.
How big can you run? Bench and pilot through 50,000 L stainless for qualified microbial/fungal programs.
Can you meet clinical specs for therapeutic enzymes? Yes—phase-appropriate analytics, residuals, endotoxin/bioburden control, and DP/lyo where indicated; we’ll show the validation footprint before commitment.

Summary — why MycoVista for microbial proteins & enzymes

Closing context: Microbial programs reward rigor. Hosts and feeds will do what physics allows; filters and columns will do what pressure and chemistry permit; auditors will ask for proof and then ask again. We build the whole system—strain, process, analytics, formulation, and documents—so your enzyme or protein is not a lab result but a released lot that behaves at campaign scale. That is the promise of Design → Data → Decision, delivered in San Diego and Montréal, without detours.

MycoVista | San Diego, CA & Montréal, Canada
Start Program Onboarding → Share target, activity units, presentation, route/dose, desired scale, and stability goals. We’ll return a design space, control strategy, and a documented path to GMP.

EN / FR support available.